| Dec 31,
2022 | Dec 31,
2023 |
|---|
| Net loss and comprehensive loss | -27,662,077 | -13,127,648 |
|---|
| Change in fair value of voting agreement derivative | 213,000 | - |
|---|
| Loss on forfeited deposit (Notes 5, 9, and 16) | - | -970,026 |
|---|
| Change in fair value of assets, net (Note 6) | - | 3 |
|---|
| Equity in net losses of affiliate | 135,155 | 218,663 |
|---|
| Depreciation | 704,681 | 638,507 |
|---|
| Stock-based compensation | 19 | 4 |
|---|
| Prepaid expenses and other assets | -90,379 | 40,766 |
|---|
| Accounts payable | 5 | 2 |
|---|
| Accrued liabilities | 429,298 | -36,226 |
|---|
| Accrued interest | - | 223,271 |
|---|
| Net cash used in operating activities | -2,265,770 | -2,455,612 |
|---|
| Deposits | 1 | - |
|---|
| Purchase of equity method investment | 3 | - |
|---|
| Purchase of property, plant, and equipment | 11 | 3 |
|---|
| Net cash used in investing activities | -14,368,944 | -2,533,653 |
|---|
| Proceeds from related party line of credit | - | 400,000 |
|---|
| Proceeds from issuance of common stock | 3 | 880,000 |
|---|
| Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs | 9 | 3 |
|---|
| Payments to issuance costs for issuance of common stock and warrants issued in cashless conversion of related party line of credit | - | 10,000 |
|---|
| Proceeds from warrants exercised | - | 210,000 |
|---|
| Net cash provided by financing activities | 16 | 5 |
|---|
| NET DECREASE IN CASH | -867,991 | -404,515 |
|---|
| Transfer from due to related party to related party LOC | - | 392,194 |
|---|
| Transfer from deposit on equipment to prepaid expenses and other assets | - | 139,617 |
|---|
| Related party LOC in exchange for common stock for EB-5 program | - | -880,000 |
|---|
| Related party LOC in exchange for common stock and warrants | - | -3,619,789 |
|---|
| Adjustment to construction in progress for cancellation of agreement | - | -2,682,000 |
|---|
| Due to others for purchase of common stock in Alterola Biotech, Inc. | 2 | - |
|---|